Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 10/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747646 | 0.82 | HSD17B10 (0.52) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL67991 | 0.81 | HSD17B10 (0.56) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL2481401 | 0.78 | HSD17B10 (0.36) | HSD17B10ESR1CA12CA1CA2 | |
| SCHEMBL11725428 | 0.77 | HSD17B10 (0.46) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL9006588 | 0.76 | TYR (0.41) | HSD17B10ESR1CA12CA1CA2 | |
| SCHEMBL8779862 | 0.76 | ITGB2 (0.50) | HSD17B10CYP3A4HPGD | |
| SCHEMBL31490395 | 0.74 | CYP3A4 (0.42) | HSD17B10ESR1ESR2CYP3A4HPGD | |
| SCHEMBL3793217 | 0.74 | PDE7A (0.41) | HSD17B10HPGD | |
| SCHEMBL13461858 | 0.74 | LMNA (0.41) | HSD17B10CYP3A4HPGDALOX15ADRA1A | |
| SCHEMBL1128366 | 0.74 | CYP3A4 (0.42) | HSD17B10ESR1ESR2CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0331144-B1 | 3-SUBSTITUTED PARA-AMINO PHENOLS, PROCESS FOR THEIR PREPARATION, THEIR USE IN DYEING KERATENIC FIBRES AND INTERMEDIATES USED IN THE PREPARATION PROCESS | L'OREAL (FR) | 1993-06-09 | — | — | EP | claimed |
| EP-0331144-A2 | 3-Substituted para-amino phenols, process for their preparation, their use in dyeing keratenic fibres and intermediates used in the preparation process | L'OREAL (FR) | 1989-09-06 | — | — | EP | claimed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-7129234-B2 | Phenyl heterocyclyl ethers | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1377550-B9 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1377550-B1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| EP-1377550-A1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1313701-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002083643-A1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002018333-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-0331144-B1 | 3-SUBSTITUTED PARA-AMINO PHENOLS, PROCESS FOR THEIR PREPARATION, THEIR USE IN DYEING KERATENIC FIBRES AND INTERMEDIATES USED IN THE PREPARATION PROCESS | L'OREAL (FR) | 1993-06-09 | — | — | EP | disclosed |
| EP-0331144-A2 | 3-Substituted para-amino phenols, process for their preparation, their use in dyeing keratenic fibres and intermediates used in the preparation process | L'OREAL (FR) | 1989-09-06 | — | — | EP | disclosed |
| US-4042705-A | 1-Methyl-2-(phenyl-oxymethyl)-5-nitro-imidazoles and process for their manufacture | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | HSD17B10 454/4885TTR 3026/4885ESR1 3152/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | HSD17B10 4655/4885TTR 4832/4885ESR1 1898/4885 |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | HSD17B10 1506/4885TTR 4463/4885ESR1 260/4885 |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | HSD17B10 1506/4885TTR 4463/4885ESR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.